RXRX Q1 2026 Earnings EPS Beat Despite No Revenue Stock Slips 32 XYL Q1 2026 Earnings EPS Beat Drives Modest Stock Uptick UG Q2 2025 Earnings Profitability Maintained Amid Modest Stock Reaction Kura Oncology Q1 2026 Earnings Wider Loss as Clinical Progress Continues SLM Q1 2026 Earnings EPS Surges Past Estimates on Strong Credit and Cost Control CRESY Q1 2026 Earnings Strong EPS Performance Despite Market Headwinds